Top in hem/onc: Blood thinners in women with miscarriage history; breast cancer risks
Click Here to Manage Email Alerts
Recent data suggest that the use of blood thinners may be unnecessary in women with a history of recurrent pregnancy loss and inherited thrombophilia, according to researchers.
The study — presented at the American Society of Hematology’s Annual Meeting and Exposition — revealed a higher rate of treatment-related adverse events among women who received antithrombotic therapy, leading researchers to advise against routine use in women with recurrent miscarriages and inherited thrombophilia. It was the top story in hematology/oncology last week.
The second top story was about a model that predicted the risk for immune-related adverse events in patients with early-stage, high-risk breast cancer. Researchers said the findings may help clinicians be more diligent with monitoring during and after treatment.
Read these and more top stories in hematology/oncology below:
Use of blood thinners may be unnecessary in women with recurrent pregnancy loss
The use of low-molecular-weight heparin among pregnant women with a history of recurrent miscarriage and inherited thrombophilia had no effect on the live birth rate, results from the phase 3 ALIFE2 trial showed. Read more.
Model predicts risk for immune-related adverse events in breast cancer subset
A symptom pattern model predicted risk for immune-related adverse events among women with early-stage, high-risk breast cancer, according to an analysis of the phase 2 I-SPY2 trial presented at San Antonio Breast Cancer Symposium. Read more.
BLOG: Navigating complexities of work-life balance
In this blog, Maryam Lustberg, MD, MPH, discusses the challenges of balancing work and family, and that “one-size prescriptive recommendations of ‘just say no’ or ‘family first’ don’t always resonate.” Read more.
Study of CAR-T for patients with non-Hodgkin lymphoma, HIV yields 'reassuring' results
Chimeric antigen receptor T cells demonstrated acceptable efficacy with no additional safety concerns when administered to patients with non-Hodgkin lymphoma and HIV, retrospective study results showed. Read more.
VIDEO: Momelotinib benefits maintained at 24 weeks in patients with anemic myelofibrosis
In this video, Aaron T. Gerds, MD, MS, an assistant professor at the Cleveland Clinic Taussig Cancer Institute, discusses updated results from the Momentum phase 3 study presented at the ASH Annual Meeting and Exposition. Watch video.